TMPRSS2 and pachyonychia congenita: Studies on TMPRSS2 were mainly conducted in prostate cancer (PC) due to its high expression in prostate epithelium luminal cells: in this respect, cancer cells showed higher TMPRSS2 expression both in primary and advanced or metastatic PCs [19,20].